Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.

ABSTRACT:

Introduction

The phase II JO25567 study compared the efficacy and safety of erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).

Objective

Our objective is to provide updated analyses of safety and the assessment of manageability of specific adverse events.

Methods

Patients with stage IIIB/IV or recurrent, non-squamous, EGFR mutation-positive NSCLC were randomized to receive erlotinib plus bevacizumab or erlotinib. The primary endpoint was progression-free survival. Adverse event frequency rates, predictability and manageability, reasons for discontinuation, time to onset, and outcomes of specific adverse events were analyzed.

Results

The s

SUBMITTER: Kato T 

PROVIDER: S-EPMC5808045 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature